ISK ltd - "thinking out of the box" drugs

ISK Ltd is a clinically oriented company developing novel drugs based on the discovery of novel genes encoding novel human peptide hormones. These novel genes are encoded in 95% of the human genome; in this region, scientists lack the tools to search for new genes. Based on our novel AI technology, we discovered new genes and applied them in successful clinical trials. The company is developing novel drugs to treat cancer, metabolic, and neurodegenerative diseases. The assets include:

1. Nerofe - a new peptide hormone encoded by a novel gene we have discovered. Nerofe activates the first anti-cancer-specific nuclear immunotherapy by activating its overexpressed nuclear receptor, ST2, in cancer cells. Nerofe is now in two phase 1b trials in the USA with exciting results (one trial in Miami University, FL, and the other in Georgetown University in Washington D.C.. Both trials are IITs. We are actively collaborating with more medical centers in the USA (among them are MSKCC and Northwell Health) to open more clinical trials in the areas of breast cancer, GI tract tumors, GBM, and meningioma.
2. We have discovered 4 novel peptide hormones in the human brain. These peptide hormones are statistically strongly related to ALS/Parkinson's disease/Alzheimer's disease, and dementia. One of the peptide hormones strongly regulates activated glial cells and is ready to start phase 2 with AD/PD patients.
3. APC1 is a novel peptide hormone, a novel gene we have discovered. APC1 strongly increases the expression of the HER2 receptor in triple-negative breast cancer cells and transforms them to become HER2+ breast cancer cells, responding to anti-HER2 therapy. This was also seen in low-expressing HER2 breast tumors.
4. AI Genome - a novel deterministic AI genomic technology that allows reading any genome, including human and animal genomes, and searching for new peptide hormone genes, receptors, and enzymes. This technology is based on the matching of 3D structures to DNA sequences